Short Interest in Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Declines By 94.9%

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totaling 64 shares, a drop of 94.9% from the December 31st total of 1,266 shares. Based on an average trading volume of 41,603 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 41,603 shares, the short-interest ratio is currently 0.0 days.

Enzon Pharmaceuticals Price Performance

Shares of Enzon Pharmaceuticals stock traded down $0.00 during trading on Wednesday, reaching $0.07. 5,000 shares of the company traded hands, compared to its average volume of 82,679. The firm has a market capitalization of $4.99 million, a PE ratio of -1.34 and a beta of 0.02. The company has a 50 day moving average price of $0.04 and a 200-day moving average price of $0.06. Enzon Pharmaceuticals has a 1-year low of $0.03 and a 1-year high of $0.18.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.02) earnings per share for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.